Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

May 30, 2018

Study Completion Date

May 30, 2018

Conditions

Gastroenteropancreatic Neuroendocrine Tumor

Trial Locations (5)

National Translational Research Group, East Setauket

Mercy Medical Center, Baltimore

Oncology Specialists of Charlotte, Charlotte

Ochsner Medical Center Kenner, Kenner

The University of Arizona Cancer Center, Tucson